Izervay™ Sample Consent and Eylea®HD form now available

November 10, 2023

Dear OMIC Insureds:

We are pleased to announce the release of a consent form for FDA-approved IZERVAY™ (Avacincaptad pegol) Treatment for Geographic Atrophy, a form of Dry Age-Related Macular Degeneration.

Additionally, The Intravitreal Injection of Eylea®HD 8mg (aflibercept) form is now available.

If you have questions regarding this information, please contact us. Remember that you may contact the Risk Management Hotline for confidential assistance at riskmanagement@omic.com or call the Risk Management Hotline at 1-800-562-6642 and choose option 4.

Sincerely,

Linda D. Harrison, PhD
Vice President, OMIC Risk Management

CONFIDENTIALITY NOTICE: This correspondence is intended only for the person or entity to which it is addressed and may contain information that is privileged, confidential or otherwise protected from disclosure. Dissemination, distribution or copying of this e-mail or the information herein by anyone other than the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, is prohibited. If you have received this e-mail in error, please notify us at riskmanagement@omic.com and destroy the original message and all copies.
______________________________________________

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Six reasons OMIC is the best choice for ophthalmologists in America.

Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $90 Million to our members through dividends.

Risk Management

Izervay™ Sample Consent and Eylea®HD form now available